Pas de connexion internet — affichage de la version enregistrée de la page.

Arrowhead Pharmac…

USUSD
← Vers le screener
US:ARWRLSE:0HI3

Arrowhead Pharmaceuticals Inc (US:ARWR) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
arrowheadpharma.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
Pasadena, United States
PDG
Dr. Christopher R. Anzalone Ph.D.
Employés
711
Fondée
2004
Actions en circulation
141.25 M au 2026-07-30
Flottant
122.45 M
Capitalisation boursière
9.22 Md USD
Initiés
3.66%
Investisseurs institutionnels
85.47%
Secteur d'activité (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
Taux de distribution
0%
FCF
−75.1 M USD
Dette
181 M USD
Ancienneté du dividende
—
Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksARWR principaleUSD60.74 -1.20%actions ordinaires
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 10.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.10.53%14.83 M2026-06-30
Avoro Capital Advisors L…8.06%11.36 M2026-06-30
FMR, LLC5.71%8.04 M2026-06-30
Vanguard Portfolio Manag…4.51%6.35 M2026-06-30
Vanguard Capital Managem…4.34%6.11 M2026-06-30
State Street Corporation4.04%5.69 M2026-06-30
iShares Trust-iShares Co…3.5%4.93 M2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 M2026-06-30
NORGES BANK2.77%3.9 M2026-06-30
Invesco Ltd.2.76%3.88 M2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 M2026-01-02
Geode Capital Management…2.51%3.53 M2026-06-30
Fred Alger Management, L…2.34%3.3 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 M2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 M2026-07-31
Invesco Exchange-Traded…1.27%1.79 M2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 M2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 M2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 M2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12